Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 241)
Posted On: 02/28/2018 5:06:10 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is Uniquely Positioned within the Cannabis Industry
- Cannabis deals in Canada cross the billion-dollar mark
- DehydraTech™ offers new and innovative methods of oral delivery
- Committed to high quality products using revolutionary technology
- The only company in the world with patents for this innovative edible technology
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) expects to benefit significantly as cannabis deals in Canada cross the billion-dollar mark in anticipation of the legalization of recreational cannabis, which is only months away (http://nnw.fm/7r6O6). Its newly developed oral digestion technology, DehydraTECH™, is a complementary layer that works with other R&D being done on cannaboids. LXRP has been awarded a patent in the U.S. and Australia, with patents pending in 40 more countries, for the improved delivery (oral or ingestible) of all non-psychoactive cannabinoids. As the only company in the world with patents for this innovative edible technology, LXRP is in a unique position to work alongside other cannabis industry players, creating partnerships rather than competitors.
DehydraTECH allows for faster delivery time, lower dosages and shorter treatment regimens. Oral ingestion of the client drug eliminates unhealthy practices of inhalation dosing. It improves the absorption rate, by as much as five to 10 times, of non-steroid anti-inflammatory drugs (NSAIDs), vitamins, cannabinoids and even nicotine. Delivery time, the time it takes from ingestion to payload molecules reaching the bloodstream, is reduced from the 60-90 minutes of current methods to a mere 15-25 minutes. High concentrations of unhealthy sugars or sweeteners are no longer needed to mask the bitter taste, and side effects are reduced, improving the bioavailability of its client drug. This provides an opportunity for new and innovative methods of oral delivery.
LXRP is committed to finding new ways to partner with companies in order to deliver high quality products, leveraging its technology that allows Lexaria to partner with, instead of compete against, other successful names in the cannabis industry. Recently, LXRP partnered with Cannfections Group Inc. to create high quality chocolate edibles using its oral technology. It continues to develop quality product lines in sports nutrition, teas, tablets, pills and beverages, using DehydraTech for optimal delivery.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Cannabis deals in Canada cross the billion-dollar mark
- DehydraTech™ offers new and innovative methods of oral delivery
- Committed to high quality products using revolutionary technology
- The only company in the world with patents for this innovative edible technology
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) expects to benefit significantly as cannabis deals in Canada cross the billion-dollar mark in anticipation of the legalization of recreational cannabis, which is only months away (http://nnw.fm/7r6O6). Its newly developed oral digestion technology, DehydraTECH™, is a complementary layer that works with other R&D being done on cannaboids. LXRP has been awarded a patent in the U.S. and Australia, with patents pending in 40 more countries, for the improved delivery (oral or ingestible) of all non-psychoactive cannabinoids. As the only company in the world with patents for this innovative edible technology, LXRP is in a unique position to work alongside other cannabis industry players, creating partnerships rather than competitors.
DehydraTECH allows for faster delivery time, lower dosages and shorter treatment regimens. Oral ingestion of the client drug eliminates unhealthy practices of inhalation dosing. It improves the absorption rate, by as much as five to 10 times, of non-steroid anti-inflammatory drugs (NSAIDs), vitamins, cannabinoids and even nicotine. Delivery time, the time it takes from ingestion to payload molecules reaching the bloodstream, is reduced from the 60-90 minutes of current methods to a mere 15-25 minutes. High concentrations of unhealthy sugars or sweeteners are no longer needed to mask the bitter taste, and side effects are reduced, improving the bioavailability of its client drug. This provides an opportunity for new and innovative methods of oral delivery.
LXRP is committed to finding new ways to partner with companies in order to deliver high quality products, leveraging its technology that allows Lexaria to partner with, instead of compete against, other successful names in the cannabis industry. Recently, LXRP partnered with Cannfections Group Inc. to create high quality chocolate edibles using its oral technology. It continues to develop quality product lines in sports nutrition, teas, tablets, pills and beverages, using DehydraTech for optimal delivery.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)